Keywords
Last Name
Institution

STACEY L BERG

TitleAssociate Dean
InstitutionBaylor College of Medicine
DepartmentVice President and Dean for Research
AddressDepartment of Pediatrics - Hem/Onc Clinical Research
1102 Bates St., C1540
Houston TX 77030
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Pediatrics
    DivisionPediatrics-Hem/Onc Clin Research

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Medical Ethics and Health Policy
    DivisionCtr for Med Ethics & Health Policy


    Collapse Additional Tools and Researcher Information 
    Collapse Faculty Mentor
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lin FY, Bergstrom K, Person R, Bavle A, Ballester LY, Scollon S, Raesz-Martinez R, Jea A, Birchansky S, Wheeler DA, Berg SL, Chintagumpala MM, Adesina AM, Eng C, Roy A, Plon SE, Parsons DW. Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle. Cold Spring Harb Mol Case Stud. 2016 Sep; 2(5):a001057. PMID: 27626068; PMCID: PMC5002928.
    2. Unguru Y, Fernandez CV, Bernhardt B, Berg S, Pyke-Grimm K, Woodman C, Joffe S. An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer. J Natl Cancer Inst. 2016 Jun; 108(6):djv392. PMID: 26825103.
      View in: PubMed
    3. Berg SL, Parsons DW. The Pharmacogenomics of Vincristine-Induced Neuropathy: On Pins and Needles. JAMA Oncol. 2015 May 28. PMID: 26181361.
      View in: PubMed
    4. Scollon S, Bergstrom K, Kerstein RA, Wang T, Hilsenbeck SG, Ramamurthy U, Gibbs RA, Eng CM, Chintagumpala MM, Berg SL, McCullough LB, McGuire AL, Plon SE, Parsons DW. Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Med. 2014; 6(9):69. PMID: 25317207; PMCID: PMC4195891.
    5. Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M, Reaman GH, Scorsone K, Sung L, Dolan ME, Berg SL. Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2014 Oct; 74(4):831-8. PMID: 25119182; PMCID: PMC4282931.
    6. Ryu RJ, Eyal S, Kaplan HG, Akbarzadeh A, Hays K, Puhl K, Easterling TR, Berg SL, Scorsone KA, Feldman EM, Umans JG, Miodovnik M, Hebert MF. Pharmacokinetics of doxorubicin in pregnant women. Cancer Chemother Pharmacol. 2014 Apr; 73(4):789-97. PMID: 24531558; PMCID: PMC3982413.
    7. Zhang N, Scorsone K, Ge G, Kaffes CC, Dobrolecki LE, Mukherjee M, Lewis MT, Berg S, Stephan CC, Pati D. Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy. J Biomol Screen. 2014 Jul; 19(6):878-89. PMID: 24525869.
      View in: PubMed
    8. Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, Su J, Goldman S, Kieran MW, Kun L, Boyett J, Stewart C. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer. 2013 Apr; 60(4):627-32. PMID: 23002039; PMCID: PMC3573253.
    9. Muscal JA, Scorsone KA, Zhang L, Ecsedy JA, Berg SL. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs. 2013 Feb; 31(1):39-45. PMID: 22669335; PMCID: PMC3655801.
    10. Muscal JA, Sun Y, Nuchtern JG, Dauser RC, McGuffey LH, Gibson BW, Berg SL. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol. 2012 Apr; 69(4):943-7. PMID: 22109830; PMCID: PMC3685292.
    11. Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol. 2012 Feb; 106(3):643-9. PMID: 21968943; PMCID: PMC3518022.
    12. Potter SL, Berg S, Ingle AM, Krailo M, Adamson PC, Blaney SM. Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer. 2012 Mar; 58(3):362-5. PMID: 21910214; PMCID: PMC3242923.
    13. Horton TM, Berg SL. Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr. 2011 May; 170(5):555-9. PMID: 21190039.
      View in: PubMed
    14. Berg SL, Cairo MS, Russell H, Ayello J, Ingle AM, Lau H, Chen N, Adamson PC, Blaney SM. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol. 2011 Jan 20; 29(3):316-23. PMID: 21149673; PMCID: PMC3056465.
    15. Beaty O, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, Voss S, Ivy SP, Adamson PC. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Sep; 55(3):440-5. PMID: 20658614; PMCID: PMC4665115.
    16. Berg SL, Winick N, Ingle AM, Adamson PC, Blaney SM. Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2010 Jul 15; 55(1):119-22. PMID: 20486176; PMCID: PMC2911979.
    17. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009 Aug; 8(8):2232-42. PMID: 19671751; PMCID: PMC3741063.
    18. Berg SL. When too much is just enough: what do oncologists tell parents? Pediatr Blood Cancer. 2009 Apr; 52(4):437-8. PMID: 19058206.
      View in: PubMed
    19. Bruce CR, Berg SL, McGuire AL. Please don't call my mom: pediatric consent and confidentiality. Clin Pediatr (Phila). 2009 Apr; 48(3):243-6. PMID: 19074356.
      View in: PubMed
    20. Kilburn LB, Bonate PL, Blaney SM, McGuffey L, Nuchtern JG, Dauser R, Thompson P, Gibson BW, Berg SL. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemother Pharmacol. 2009 Jul; 64(2):335-40. PMID: 19043710.
      View in: PubMed
    21. Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, Ellis KJ, Renbarger J, Berg SL. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol. 2009 Jul; 64(2):243-51. PMID: 19020877.
      View in: PubMed
    22. Bomgaars L, Thompson P, Berg S, Serabe B, Aleksic A, Blaney S. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr Blood Cancer. 2008 Oct; 51(4):504-8. PMID: 18561175; PMCID: PMC4063282.
    23. Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC. Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist. 2008 Jun; 13(6):679-89. PMID: 18586923.
      View in: PubMed
    24. Jacob E, Scorsone K, Blaney SM, D'Argenio DZ, Berg SL. Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatr Blood Cancer. 2008 Apr; 50(4):757-60. PMID: 17849472; PMCID: PMC2975705.
    25. Adams DM, Zhou T, Berg SL, Bernstein M, Neville K, Blaney SM. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):549-53. PMID: 17941066.
      View in: PubMed
    26. Berg SL. Ethical challenges in cancer research in children. Oncologist. 2007 Nov; 12(11):1336-43. PMID: 18055854.
      View in: PubMed
    27. Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 1; 25(31):4922-8. PMID: 17971589.
      View in: PubMed
    28. Blumer J, Berg S, Adamson PC, Loew T, Rossi G, Hastings C. Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. Pediatr Blood Cancer. 2007 Oct 15; 49(5):687-93. PMID: 17120240.
      View in: PubMed
    29. Bernardi RJ, Bomgaars L, Fox E, Balis FM, Egorin MJ, Lagattuta TF, Aikin A, Whitcomb P, Renbarger J, Lieberman FS, Berg SL, Blaney SM. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. 2008 Jul; 62(2):355-61. PMID: 17909804.
      View in: PubMed
    30. Stapleton SL, Thompson PA, Ou CN, Berg SL, McGuffey L, Gibson B, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol. 2008 Apr; 61(4):647-52. PMID: 17541590.
      View in: PubMed
    31. Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, Camitta BM, Dreyer ZE, Bomgaars LR. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007 May; 59(6):847-53. PMID: 17136402.
      View in: PubMed
    32. Berg SL, Brueckner C, Nuchtern JG, Dauser R, McGuffey L, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer Chemother Pharmacol. 2007 May; 59(6):743-7. PMID: 16953392.
      View in: PubMed
    33. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, Shohet JM. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006 Sep; 5(9):2358-65. PMID: 16985070.
      View in: PubMed
    34. Bomgaars L, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006 Jan; 46(1):50-5. PMID: 15768380.
      View in: PubMed
    35. Whitney SN, Ethier AM, Frugé E, Berg S, McCullough LB, Hockenberry M. Decision making in pediatric oncology: who should take the lead? The decisional priority in pediatric oncology model. J Clin Oncol. 2006 Jan 1; 24(1):160-5. PMID: 16382126.
      View in: PubMed
    36. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23. PMID: 16292537.
      View in: PubMed
    37. Berg SL, Bonate PL, Nuchtern JG, Dauser R, McGuffey L, Bernacky B, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res. 2005 Aug 15; 11(16):5981-3. PMID: 16115942.
      View in: PubMed
    38. Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20; 23(15):3376-82. PMID: 15908649.
      View in: PubMed
    39. Blaney SM, Balis FM, Berg S, Arndt CA, Heideman R, Geyer JR, Packer R, Adamson PC, Jaeckle K, Klenke R, Aikin A, Murphy R, McCully C, Poplack DG. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 1; 23(7):1555-63. PMID: 15735131.
      View in: PubMed
    40. Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 1; 11(5):1884-9. PMID: 15756014.
      View in: PubMed
    41. Berg SL, Chamberlain MC. Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res. 2005; 125:121-46. PMID: 16211887.
      View in: PubMed
    42. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004 Dec 1; 22(23):4804-9. PMID: 15570082.
      View in: PubMed
    43. Chintagumpala M, Blaney SM, Bomgaars LR, Aleksic A, Kuttesch JF, Klenke RA, Berg SL. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 1; 22(21):4394-400. PMID: 15514381.
      View in: PubMed
    44. Zhang L, Plon SE, Nuchtern JG, Burlingame S, Blaney S, Rousseau R, Berg S. Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. Anticancer Drugs. 2004 Oct; 15(9):883-8. PMID: 15457129.
      View in: PubMed
    45. Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ, Klenke R, Berg SL, Blaney SM. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004 Oct 1; 22(19):3916-21. PMID: 15459213.
      View in: PubMed
    46. Neville K, Blaney S, Bernstein M, Thompson P, Adams D, Aleksic A, Berg S. Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. Clin Cancer Res. 2004 Aug 1; 10(15):5072-5. PMID: 15297409.
      View in: PubMed
    47. Berg SL, Aleksic A, McGuffey L, Dauser R, Nuchtern J, Bernacky B, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Aug; 54(2):127-30. PMID: 15150671.
      View in: PubMed
    48. Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res. 2004 Apr 1; 10(7):2525-9. PMID: 15073132.
      View in: PubMed
    49. Berg SL, Stone J, Xiao JJ, Chan KK, Nuchtern J, Dauser R, McGuffey L, Thompson P, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jul; 54(1):85-8. PMID: 15042312.
      View in: PubMed
    50. Thompson PA, Berg SL, Aleksic A, Kerr JZ, McGuffey L, Dauser R, Nuchtern JG, Hausheer F, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jun; 53(6):527-32. PMID: 14997342.
      View in: PubMed
    51. Renbarger J, Aleksic A, McGuffey L, Dauser R, Berg S, Blaney S. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jan; 53(1):39-42. PMID: 14551735.
      View in: PubMed
    52. Thompson P, Balis F, Serabe BM, Berg S, Adamson P, Klenke R, Aiken A, Packer R, Murry DJ, Jakacki R, Blaney SM. Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. Cancer Chemother Pharmacol. 2003 Nov; 52(5):417-23. PMID: 12879279.
      View in: PubMed
    53. Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 1; 21(1):143-7. PMID: 12506183.
      View in: PubMed
    54. Berg SL, Chamberlain MC. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep. 2003 Jan; 5(1):29-40. PMID: 12493148.
      View in: PubMed
    55. Egorin MJ, Zuhowski EG, McCully CM, Blaney SM, Kerr JZ, Berg SL, Balis FM. Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res. 2002 Jul; 8(7):2437-42. PMID: 12114450.
      View in: PubMed
    56. Murry DJ, Cherrick I, Salama V, Berg S, Bernstein M, Kuttesch N, Blaney SM. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol. 2002 Feb; 24(2):130-3. PMID: 11990699.
      View in: PubMed
    57. Chintagumpala M, Berg S, Blaney SM. Treatment controversies in medulloblastoma. Curr Opin Oncol. 2001 May; 13(3):154-9. PMID: 11307057.
      View in: PubMed
    58. Berg S, Serabe B, Aleksic A, Bomgaars L, McGuffey L, Dauser R, Durfee J, Nuchtern J, Blaney S. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother Pharmacol. 2001 May; 47(5):385-90. PMID: 11391852.
      View in: PubMed
    59. Kerr JZ, Berg SL, Dauser R, Nuchtern J, Egorin MJ, McGuffey L, Aleksic A, Blaney S. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol. 2001 May; 47(5):411-4. PMID: 11391856.
      View in: PubMed
    60. Kerr JZ, Berg S, Blaney SM. Intrathecal chemotherapy. Crit Rev Oncol Hematol. 2001 Mar; 37(3):227-36. PMID: 11248578.
      View in: PubMed
    61. Bomgaars L, Berg SL, Blaney SM. The development of camptothecin analogs in childhood cancers. Oncologist. 2001; 6(6):506-16. PMID: 11743213.
      View in: PubMed
    62. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res. 2001 Jan; 7(1):32-7. PMID: 11205914.
      View in: PubMed
    63. Berg SL, Blaney SM, Sullivan J, Bernstein M, Dubowy R, Harris MB. Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 2000 Nov-Dec; 22(6):506-9. PMID: 11132217; PMCID: PMC4008246.
    64. Long L, Berg SL, Roy SK, McCully CL, Song-Yoo HW, Moschel RC, Balis FM, Dolan ME. Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates. Clin Cancer Res. 2000 Sep; 6(9):3662-9. PMID: 10999759.
      View in: PubMed
    65. Riva L, Blaney SM, Dauser R, Nuchtern JG, Durfee J, McGuffey L, Berg SL. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clin Cancer Res. 2000 Mar; 6(3):994-7. PMID: 10741726.
      View in: PubMed
    66. Kitchen BJ, Moser A, Lowe E, Balis FM, Widemann B, Anderson L, Strong J, Blaney SM, Berg SL, O'Brien M, Adamson PC. Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. J Pharmacol Exp Ther. 1999 Nov; 291(2):870-4. PMID: 10525111.
      View in: PubMed
    67. Serabe BM, Murry DJ, Dauser R, Nuchtern J, Durfee J, McGuffey L, Berg S, Blaney SM. Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. Cancer Chemother Pharmacol. 1999; 43(5):415-8. PMID: 10100598.
      View in: PubMed
    68. Berg SL, Reid J, Godwin K, Murry DJ, Poplack DG, Balis FM, Ames MM. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):26-30. PMID: 10029808.
      View in: PubMed
    69. Berg SL, Murry DJ, McCully CL, Godwin K, Balis FM. Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. Clin Cancer Res. 1998 Nov; 4(11):2891-4. PMID: 9829757.
      View in: PubMed
    70. Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60. PMID: 9516923.
      View in: PubMed
    71. Berg SL, Blaney SM, Adamson PC, O'Brien M, Poplack DG, Arndt C, Blatt J, Balis FM. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6. PMID: 9440741.
      View in: PubMed
    72. Adamson PC, Reaman G, Finklestein JZ, Feusner J, Berg SL, Blaney SM, O'Brien M, Murphy RF, Balis FM. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997 Nov; 15(11):3330-7. PMID: 9363862.
      View in: PubMed
    73. Blaney SM, Seibel NL, O'Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis FM. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr; 15(4):1538-43. PMID: 9193350.
      View in: PubMed
    74. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen JC, Sallan SE, Jakacki RI, Lange BJ, Reaman GH, Horowitz ME, Poplack DG, Balis FM. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 1; 78(3):527-31. PMID: 8697400.
      View in: PubMed
    75. Grem JL, Politi PM, Berg SL, Benchekroun NM, Patel M, Balis FM, Sinha BK, Dahut W, Allegra CJ. Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. Biochem Pharmacol. 1996 Jun 28; 51(12):1649-59. PMID: 8687480.
      View in: PubMed
    76. Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, Noone MH, Denicoff AM, Barnes CS, Gossard MR, Fetsch PA, Berg SL, Balis FM, Venzon DJ, O'Shaughnessy JA. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol. 1996 Apr; 14(4):1173-84. PMID: 8648372.
      View in: PubMed
    77. Berg SL. Status of new anthrapyrazole and pyrazoloacridine derivatives. Crit Rev Oncol Hematol. 1996 Mar; 22(2):79-87. PMID: 8679102.
      View in: PubMed
    78. Fisherman JS, Cowan KH, Noone M, Denicoff A, Berg S, Poplack D, Balis F, Venzon D, McCabe M, Goldspiel B, Chow C, Ognibene FP, O'Shaughnessy J. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol. 1996 Mar; 14(3):774-82. PMID: 8622023.
      View in: PubMed
    79. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, Dilsizian V, Avila N, Jarosinski P, Balis FM, Poplack DG, Horowitz ME. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996 Feb; 14(2):362-72. PMID: 8636745.
      View in: PubMed
    80. Berg SL, Gerson SL, Godwin K, Cole DE, Liu L, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. Cancer Res. 1995 Oct 15; 55(20):4606-10. PMID: 7553637.
      View in: PubMed
    81. Adamson PC, Balis FM, Belasco JE, Lange B, Berg SL, Blaney SM, Craig C, Poplack DG. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995 Sep 15; 55(18):4069-72. PMID: 7664282.
      View in: PubMed
    82. Berg SL, Poplack DG. Advances in the treatment of meningeal cancers. Crit Rev Oncol Hematol. 1995 Aug; 20(1-2):87-98. PMID: 7576199.
      View in: PubMed
    83. Berg SL, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP, Cowan KH, Balis FM. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol. 1995 Aug; 13(8):2039-42. PMID: 7636546.
      View in: PubMed
    84. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994 Aug; 12(8):1621-9. PMID: 7913721.
      View in: PubMed
    85. Berg S, Balis FM, McCully CL, Poplack DC. Re: Toxicity of intrathecal melphalan. J Natl Cancer Inst. 1994 Mar 16; 86(6):463. PMID: 8120922.
      View in: PubMed
    86. Berg SL, Cowan KH, Balis FM, Fisherman JS, Denicoff AM, Hillig M, Poplack DG, O'Shaughnessy JA. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst. 1994 Jan 19; 86(2):143-5. PMID: 7903702.
      View in: PubMed
    87. Berg SL, Balis FM, Godwin KS, Poplack DG. Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the rhesus monkey. Invest New Drugs. 1993 Nov; 11(4):255-61. PMID: 8157468.
      View in: PubMed
    88. Savarese DM, Denicoff AM, Berg SL, Hillig M, Baker SP, O'Shaughnessy JA, Chow C, Otterson GA, Balis FM, Poplack DG, et al. Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol. 1993 Sep; 11(9):1795-803. PMID: 7689093.
      View in: PubMed
    89. Berg SL, Savarese DM, Balis FM, Denicoff AM, Hillig M, O'Shaughnessy JA, Poplack DG, Cowan KH. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor. Cancer Res. 1993 Jun 1; 53(11):2587-90. PMID: 7684320.
      View in: PubMed
    90. Berg SL, Balis FM, McCully CL, Godwin KS, Poplack DG. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey. Cancer Chemother Pharmacol. 1993; 32(4):310-4. PMID: 8324873.
      View in: PubMed
    91. Weinberger M, Berg SL, Feuerstein IM, Pizzo PA, Witebsky FG. Disseminated infection with Mycobacterium gordonae: report of a case and critical review of the literature. Clin Infect Dis. 1992 Jun; 14(6):1229-39. PMID: 1623079.
      View in: PubMed
    92. Berg SL, Balis FM, McCully CL, Parker GA, Murphy RF, Poplack DG. Intrathecal 5-fluorouracil in the rhesus monkey. Cancer Chemother Pharmacol. 1992; 31(2):127-30. PMID: 1451233.
      View in: PubMed
    93. Berg SL, Balis FM, Zimm S, Murphy RF, Holcenberg J, Sato J, Reaman G, Steinherz P, Gillespie A, Doherty K, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol. 1992 Jan; 10(1):143-8. PMID: 1727916.
      View in: PubMed
    94. Berg SL, Balis FM, McCully CL, Godwin KS, Poplack DG. Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Cancer Res. 1991 Oct 15; 51(20):5467-70. PMID: 1913666.
      View in: PubMed
    95. Berg SL, Poplack DG. Complications of leukemia. Pediatr Rev. 1991 Apr; 12(10):313-8. PMID: 2017403.
      View in: PubMed
    96. Pasqualini T, McCalla J, Berg S, Poplack DG, Rose SR, Nisula BC, Cassorla F. Subtle primary hypothyroidism in patients treated for acute lymphoblastic leukemia. Acta Endocrinol (Copenh). 1991 Apr; 124(4):375-80. PMID: 1903235.
      View in: PubMed
    97. Berg SL, Grisell DL, DeLaney TF, Balis FM. Principles of treatment of pediatric solid tumors. Pediatr Clin North Am. 1991 Apr; 38(2):249-67. PMID: 2006077.
      View in: PubMed
    BERG's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _